Reproductive Health Matters
Volume 16, Issue 32 , Pages 18-31 , November 2008

Prevention of cervical cancer

References 

  1. Ferlay BF, Pisani P, Parkin DM. Globocan 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5 Version 2.0. Lyon: IARC Press; 2004;
  2. In:  Parkin DM,  Whelan SL,  Ferlay J,  Teo L,  Thomas DB editor. Cancer Incidence in Five Continents, Vol VIII. IARC Scientific Publications No. 155. Lyon: IARC; 2002;
  3. Cancer Registry of South Africa, Annual Report 1987.
  4. Sitas F, Madhoo J, Wessie J. Incidence of Histologically Diagnosed Cancer in South Africa, 1993–1995, National Cancer Registry of South Africa. Johannesburg: South African Institute of Medical Research; 1998;
  5. Mqoqi N, Kellet P, Sitas F, Jula M. Incidence of Histologically Diagnosed cancer in South Africa, 1998–1999. National Cancer Registry of South Africa. Johannesburg: National Health Laboratory Service; December 2004;
  6. Walker ARP, Michelow PM, Walker BF. Cervix cancer in African women in Durban, South Africa. International Journal of Gynecology and Obstetrics. 2002 Apr 30;45–46
  7. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV. Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. N Engl J Med. 2003;348:518–527
  8. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. British Journal of Cancer. 2003;88:63–73URL: http://www.nature.com/bjc/journal/v88/n1/abs/6600688a.html
  9. Munoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet. 2002 Mar 30;359(9312):1093–1101
  10. International Collaboration of Epidemiological Studies of Cervical Cancer. Carcinoma of the cervix and tobacco smoking: Collaborative reanalysis of individual data on 13, 541 women with carcinoma of the cervix and 23, 017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer. 2006;118(6):1481–1495URL: http://www3.interscience.wiley.com/cgi-bin/abstract/112099381/ABSTRACT
  11. Moreno V, Bosch FX, Munoz N, Meijer CJ, Shah KV, Walboomers JMM, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric casecontrol study. Lancet. 2002 Mar;359(9312):1085–1092URL: http://image.thelancet.com/extras/01art3030web.pdf
  12. Smith JS, Herrero R, Bosetti C, et al. Herpes Simplex Virus-2 as a human pappilomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst. 2002;94(21):1604–1613
  13. Wallin KL, Wiklun F, Luostarinen T, Angstrom T, Anttila T, Bergman F, et al. A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int J Cancer. 2002 Oct 1;101(4):371–374URL: http://www3.interscience.wiley.com/cgi-bin/abstract/97518948/ABSTRACT?CRETRY=1&SRETRY=0
  14. Sitas F, Pacella-Norman R, Carrara H, Patel M, Ruff P, Sur R, et al. The spectrum of HIV-1 related cancers in South Africa. Int J Cancer. 2000;88(3):489–492URL: http://www3.interscience.wiley.com/cgi-bin/abstract/73504895/ABSTRACT
  15. Lomalisa P, Smith T, Guidozzi F. Human immunodeficiency virus infection and invasive cervical cancer in South Africa. Gynecol Oncol. 2000 Jun;77(3):460–463
  16. Moodley M, Mould S. Invasive cervical cancer and human immunodeficiency virus (HIV) infection in KwaZulu-Natal, South Africa. J Obstet Gynaecol. 2005;25:706–710
  17. Harris T, Burke RD, Palefsky JM, Massad LS, Yon Bang J, Anastos K, et al. Incidence of Cervical Squamous Intraepithelial Lesions Associated with HIV Serostatus, CD4 Cell counts, and Human Papillomavirus Test Results. JAMA. 2005;293:1471–1476
  18. Moodley J, Hoffman M, Carrara H, Allan B, Cooper D, Rosenberg L, et al. HIV and pre-neoplastic and neoplastic lesions of the cervix in South Africa: A casecontrol study. BMC Cancer. 2006;6:135–141
  19. Manhart LE, Koutsky LA. Do Condoms Prevent Genital HPV Infection, External Genital Warts, or Cervical Neoplasia? A Meta-Analysis. Sex Trans Dis. 2002;29:725–735
  20. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez F, et al. A controlled trial of a human papillomavirus type-16 vaccine. N Engl J Med. 2002;347:1645–1651
  21. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006;107(1):18–27URL: http://www.ob-gyn.ca/pdf/Suggested%20Readings/ForMay09_BadawiHPV_Vaccine.pdf
  22. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet. 2004 Nov;364(9447):1757–1765
  23. Harper DM, Franco EL, Wheeler CM, Moscicki A, Roteli-Martins CM, Jenkins D, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet. 2006 April;367(9518):1247–1255
  24. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliana AR, et al. Prophylactic quadrivalent human papillomavirus types 6, 11, 16, and 18 L1 virus-like particle vaccine in young women: a randomized doubleblind placebo-controlled multicentre phase 11 efficacy trial. Lancet Oncol. 2005 May;6(5):271–278
  25. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammounda D, et al. Against which Human Papillomaviurs types shall we vaccinate and screen? The International Perspective. Int J Cancer. 2004;111:278–285
  26. Summary Chapter: IARC Working Group on Cervical Cancer Screening. In:  Hakama M,  Miller AB,  Day NE editor. Screening for Cancer of the Uterine Cervix. Lyon: International Agency for Research on Cancer; 1986;p. 133–142
  27. Laara E, Day NE, Hakama M. Trends in Mortality from Cervical Cancer in the Nordic Countries: Association with organized screening programmes. Lancet. 1987 May 30;247–249
  28. IARC Working Group on Evaluation of Cervical Cancer Screening Programmes. Screening for squamous cervical cancer: the duration of low risk after negative result of cervical cytology and its implication for screening policies. Br Med J. 1986;293:659–664
  29. Hakama M, Louhivuori K. A screening programme for cervical cancer that worked. Cancer surveys. 1988;17(3):403–416
  30. Fonn S, Bloch B, Mabina M, Carpenter S, Cronje H, Maise C, et al. Prevalence of pre-cancerous lesions and cervical cancer in South Africa – a multicentre study. S Afr Med J. 2002 Feb;92(2):148–156
  31. Fonn S, Klugman B, Dehaeck K. Towards a National Screening Policy for Cancer of the Cervix in South Africa. Paper no. 31. Johannesburg: The Centre for Health Policy, Department of Community Health, Medical School, University of Witswatersrand; 1993;
  32. Baillie R. Cervical Cytology Screening: Towards the Development of a Rational Policy for the Western Cape, South Africa. Doctoral Thesis. Department of Community Health. University of Cape Town; December 1994.
  33. Cronje HS, Trumpelmann MD, Divall PD, Scott LL, Middlecote BD, De Wet JI. Cervical cytological services in the Orange Free State. Demographic Characteristics. S Afr Med J. 1989;76:116
  34. Heysteck MJ, de Jonge ET, Meyer HP, Lindeque BG. Screening for cervical neoplasia in Mamelodi – lessons from an unscreened population. S Afr Med J. 1995 Nov;85(11):1180–1182
  35. Gladwyn Leiman. ‘Project Screen Soweto’ – A planned cervical cancer screening programme in a high-risk population. The S Afr Journal of Epidemiology and Infection. 1987;2:61–68
  36. Emdon S, Gerard U, Jones R. Knowledge about and utilisation of facilities for cervical smears among black women in Johannesburg. S Afr Med J. 1984;65:289–290
  37. Smith N, Moodley J, Hoffman M. Challenges to cervical cancer screening in the Western Cape province. S Afr Med J. 2003 Jan;93(1):32–35
  38. Fonn S. Human resource requirements for introducing cervical screening – who do we need where?. S Afr Med J. 2003;93(10):901–903
  39. Michelow P, Dubb M. The implementation of a national cervical screening programme: are our cytology laboratories up to the challenge?. The S Afr Journal of Epidemiology and Infection. 2003;18:38–41
  40. Denny L, Kuhn L, Pollack A, Wright TC. Direct visual inspection for cervical cancer screening. Cancer. 2002;94(16):1699–1707URL: http://www3.interscience.wiley.com/cgi-bin/abstract/91016204/ABSTRACT
  41. Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S. A Critical Assessment of Screening Methods for Cervical Neoplasia. Int J Gynaecol Obstet. 2005 May;89 Suppl 2:S4–S12
  42. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006 Sep;119(5):1095–1101
  43. Denny L, Kuhn L, De Souza M, Pollack AE, Dupree W, Wright TC. Screen-and-Treat Approaches for Cervical Cancer Prevention in Low-Resource Settings. A Randomized Controlled Trial. JAMA. 2005;294:2173–2181URL: http://jama.ama-assn.org/cgi/content/abstract/294/17/2173
  44. Gaffikin L, Blumenthal PD, Emerson M, Limpaphayom K Royal Thai College of Obstetricians and Gynaecologist (RTCOG)/JHPIEGO Corporation Cervical Cancer Prevention Group. Safety, acceptability, and feasibility of a single-visit approach to cervical-cancer prevention in rural Thailand; a demonstration project. Lancet. 2003 Mar;361(9360):814–820

PII: S0968-8080(08)32397-0

doi: 10.1016/S0968-8080(08)32397-0

Reproductive Health Matters
Volume 16, Issue 32 , Pages 18-31 , November 2008

Article Tools

* Image Usage & Resolution